VYNE (VYNE Therapeutics) Inventories, Raw Materials & Components: $0.00 Mil (As of Mar. 2026)


VYNE VYNE Therapeutics Inc VYNE
37 GF Score
Price $0.68
GF Value $0.56
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is VYNE Therapeutics Inventories, Raw Materials & Components?

VYNE Therapeutics VYNE -0.61% 37 Inventories, Raw Materials & Components is $0.00 Mil as of Mar. 2026. GuruFocus rates VYNE with a GF Score™ of 37/100 and a GF Value™ of $0.56 (Modestly Overvalued). The stock has 5 warning signs investors should review.

VYNE Therapeutics's inventories, raw materials & components for the quarter that ended in Mar. 2026 was $0.00 Mil.

VYNE Therapeutics Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for VYNE Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VYNE Therapeutics Inventories, Raw Materials & Components Chart

VYNE Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

VYNE Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
VYNE
37GF Score
VYNE Therapeutics Inc VYNE
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VYNE Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of $0.00 Mil mean?
VYNE Therapeutics (VYNE) has a Inventories, Raw Materials & Components of $0.00 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on VYNE Therapeutics and its competitors.
Is VYNE Therapeutics' Inventories, Raw Materials & Components too high?
VYNE Therapeutics' current Inventories, Raw Materials & Components is $0.00 Mil. Overall, VYNE Therapeutics has a GF Score™ of 37/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does VYNE Therapeutics' Inventories, Raw Materials & Components compare to PLUR and MRKR?
VYNE Therapeutics' Inventories, Raw Materials & Components of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on VYNE Therapeutics and its competitors. VYNE Therapeutics's current Inventories, Raw Materials & Components is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VYNE Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, VYNE Therapeutics (VYNE) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.56, compared to a current price of $0.68 — trading 21.4% above its estimated fair value. The current Inventories, Raw Materials & Components is $0.00 Mil. VYNE Therapeutics' overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For VYNE Therapeutics (VYNE), the current Inventories, Raw Materials & Components is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VYNE Therapeutics (VYNE) Overvalued in 2026?

Based on GuruFocus' analysis, VYNE Therapeutics stock appears to be overvalued. The current stock price of $0.68 is trading 21.4% above its estimated GF Value™ of $0.56. GuruFocus considers VYNE Therapeutics to be Modestly Overvalued.

Key valuation signals for VYNE:

  • Inventories, Raw Materials & Components: $0.00 Mil
  • GF Value™: $0.56 vs. price of $0.68 (21.4% above fair value)
  • GF Score™: 37/100 with 5 warning signs

No single metric tells the full story. See the VYNE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VYNE Therapeutics Business Description

Address P.O. Box 125, Stewartsville, NJ, USA, 08886
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
37GF Score

Get the complete analysis for VYNE

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.68
Price
$0.56
GF Value